PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Ticker SymbolPRCT
Company nameProcept Biorobotics Corp
IPO dateSep 15, 2021
Founded at2021
CEODr. Reza Zadno, Ph.D.
Number of employees756
Security typeOrdinary Share
Fiscal year-endSep 15
Address150 Baytech Drive
CitySAN JOSE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code95134
Phone16502329832
Websitehttps://www.procept-biorobotics.com/
Ticker SymbolPRCT
IPO dateSep 15, 2021
Founded at2021
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data